01
NPD Roadmap & Governance
Stage-gated development roadmap with all workstreams in parallel. RACI, decision logs, risk register, and weekly operating rhythm — the backbone every early-stage biotech needs.
Science.
Strategy.
Scale.
Venture studio for biotechnology and nutrition innovation. We partner with science-led founders to close the gap between breakthrough research and fundable, revenue-generating businesses.
Scroll
We build alongside founders —
not just advise them
Niche Bioventures is a venture builder and holding company focused on the global food system transformation. We take active minority positions, embedded roles, or blended structures — always milestone-oriented and aligned with founder success.
Our sector focus spans functional nutrition, biotics & probiotics, precision fermentation, and health-linked biotech — with deep expertise in EU and international regulatory and commercial landscapes.
The Core Challenge
Great science fails.
Not from lack of innovation —
from lack of execution.
“Most biotech startups don’t fail because their science is wrong. They fail because the path from lab to market is navigated without the right structure, strategy, or commercial discipline.”
The execution gap between scientific breakthrough and commercial success is systematic, predictable — and fixable.
60%+
of startup closures driven by operational and commercial execution failures — not technology or market. CB Insights
2×
longer time to fundable milestone for startups without structured execution — and double the capital consumed.
- 01
No execution architecture
Founders operate without structured roadmaps, governance frameworks, or decision logs. Critical choices are made ad hoc, undocumented, and untraceable — creating debt that compounds as the company grows.
- 02
Sequential instead of parallel
R&D, IP strategy, regulatory navigation, scale-up planning, commercial development, and fundraising run one after another. A structured partner runs all six in parallel — cutting time to market in half.
- 03
Regulatory navigation is costly and late
Claim strategy, Novel Food classification, EFSA precedents, and territory-specific routes are discovered reactively. Assumptions are baked into product design before regulatory expertise is engaged.
- 04
IP gaps discovered at the worst moment
Freedom-to-operate analysis is deferred until funding conversations expose the risk. Late-stage IP conflicts are exponentially more expensive to resolve — and can kill a deal entirely.
- 05
Poor investor readiness
Data rooms are incomplete, financial models lack rigour, and business plans don’t reflect investor-grade thinking. Good science with poor documentation raises less — or raises later, at worse terms.
- 06
Scale-up economics underestimated
COGS models are built too late and without rigour. The lab-to-industrial gap is systematically underestimated, leading to business plans that collapse under commercial scrutiny.
Our Approach
A market-back architecture
for every workstream
We don’t consult and leave. We embed alongside founding teams, running technical, commercial, and regulatory workstreams as one integrated plan.
02
Pricing & Go-to-Market Strategy
Value-based pricing architecture, channel strategy, ideal customer profiling, and B2B sales playbook design — built from rigorous customer discovery and competitive positioning, not assumptions.
03
Regulatory-to-Commercial Alignment
Claim strategy mapped to evidence, Novel Food triage, territory-specific routes, and regulatory checkpoints integrated into launch timelines — so commercial plans reflect reality.
04
IP Strategy & FTO
Freedom-to-operate analysis, patent landscape mapping, and IP strategy from day one — not discovered during investor due diligence. Conflicts found early are solvable; late ones are deal-killers.
05
Investor Readiness & Data Room
Business plan, financial model, pitch deck, and data room to institutional-investor standards. Unit economics, COGS analysis, scenario planning, Q&A prep — raise at better terms.
06
Scale-Up & Industrial Planning
Process readiness assessment, CDMO/CMO mapping, COGS parametric modelling, and scale-up risk analysis — ensuring product economics hold at commercial volumes before capital is committed.
The Outcome
Building investable
biotech companies
80%
Success rate
- Investor-grade readiness across portfolio
- 80%+ success in strategic negotiations
- Accelerated time to first revenue milestone
Investor readiness is a state the company reaches through disciplined execution across every dimension investors scrutinise.
- 📋
Institutional-grade documentation
Data rooms, financial models, and business plans built to the standard experienced investors expect — reducing friction in every funding conversation.
- ⚖️
De-risked IP & regulatory position
FTO analysis completed, claim strategy mapped, regulatory route clear — the three questions every investor asks answered before the first meeting.
- 📈
Credible commercial traction evidence
Letters of intent, pilot agreements, and customer discovery outcomes built before the raise — transforming potential into evidence.
- 🏭
Validated scale-up economics
COGS models grounded in real process data and industrial benchmarks — investors trust companies that know what their product costs at scale.
For Startups
From lab to revenue-ready
Four structured phases that take a science-led company from discovery to investable — with embedded execution at every stage.
01
Understand the Customer
Rigorous customer discovery and validation. Define the real job-to-be-done, ideal customer profiles, value proposition, and competitive positioning — grounded in evidence, not assumptions.
02
Price, Position & Go to Market
Value-based pricing strategy, channel architecture, and a B2B sales playbook grounded in real customer discovery. We define your commercial model before you scale — so every investment decision is backed by validated market logic.
03
Execute with Structure
Embedded project management aligns technical, regulatory, operational, and commercial workstreams. Weekly rhythm, stage-gates, KPI tracking — so execution never drifts.
04
Prepare to Scale & Raise
Investor-ready data room, credible financial model, COGS validated at industrial scale, and a compelling fundraising narrative. Raise faster, at better terms, from the right investors.
For Startups
Your execution partner from science to Series A
Whether pre-seed with a validated concept or post-seed preparing for your first institutional raise, we bring the operational structure, commercial discipline, and sector expertise to accelerate your path.
- NPD governance and execution roadmap
- Regulatory strategy and claim pathway
- IP strategy and freedom-to-operate
- Investor readiness and data room build
- CDMO and partner network activation
- Flexible equity or retainer structures
For Investors
Commercial diligence & portfolio value creation
We provide independent commercial due diligence on biotech investment opportunities, and active operational support for portfolio companies navigating scale-up or commercial launch.
- Commercial viability and GTM assessment
- Regulatory risk and IP landscape review
- Unit economics and COGS validation
- Portfolio company operational support
- Independent director and NED roles
- Post-acquisition integration expertise
Sector Focus
Deep domain expertise across high-growth verticals
- Health Ingredients
- Probiotics & Prebiotics
- Postbiotics
- Precision Fermentation
- Functional Ingredients
- Nutrition & Health
- Enzyme Technology
- Food Biotech
- Cosmetics Bioactive
- Companion Animal
- Plant-Based Ingredients
- Industrial Biotech
- Pharma APIs
Foundation
A science-to-market background
built for this specific gap
Antonio Martínez
Managing Partner
A science-to-market background with the complete coverage required to industrialize and commercialize a differentiated ingredient platform — combining deep technical leadership, disciplined go-to-market execution, global scale-up experience, and extensive industry relationships across the value chain. Network spanning Spain, Europe, USA and Mainland China.
- Corporate
Leadership VP — Health Ingredients Division
Large-scale P&L leadership within a Fortune 50 corporation. Oversaw the full integration of four international acquisitions across Spain, UK, USA and Denmark, with board representation in each subsidiary. Deep operational fluency across technical, commercial and regulatory functions.
- Kerry Group
Biosearch Chief Commercial Officer — Biosearch Life
Led global commercial strategy at one of Europe’s leading probiotic ingredient companies prior to its acquisition by Kerry Group. Full ownership of key account management, pricing strategy, and go-to-market execution across international markets.
- Industry
Roles Nutrition Capital Network & International Probiotics Association
Former committee member at NCN, the leading global capital network in nutrition and ingredients. Former judge at the NutraIngredients Awards. Former board member of the International Probiotics Association.
- M&A
Advisory 50+ Due Diligence Processes
Extensive track record evaluating biotech companies from both sides of the table — as corporate acquirer and as independent advisor. Precise understanding of what institutional investors and strategic acquirers expect at every stage.
Start the Conversation
Ready to close the execution gap?
Whether you’re a seed-stage founder, a Series A company with a specific commercial or regulatory challenge, or an investor seeking independent diligence — let’s talk.
Location
Tactica HUB · Paterna, Valencia, Spain
Focus
Food & Biotech · EU · USA · China